MannKind rises after India approves insulin inhalation powder
11/12/2024 12:43
** Shares of drugmaker MannKind MNKD.O rise 2.1% to $6.81
premarket
** MNKD and partner Cipla CIPL.NS say the Central Drugs
Standard Control Organisation (CDSCO) in India has approved
MNKD's insulin inhalation powder Afrezza
** India has the second highest burden of diabetes worldwide
the companies say
** MNKD expects to ship product for CIPL by end of 2025
** Under the agreement, CIPL is responsible for obtaining
regulatory approvals to distribute Afrezza in India as well as
marketing and sales activities, while MNKD is responsible for
supplying it
** Up to last close, MNKD up 83.2% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children